Stem cell treatment to calm immune problems
Part of Immune system & allergy clinical trials.
This Phase 1 study tests an early-stage “clonal” fetal stem cell treatment to help control immune-related disorders like graft-versus-host disease (GVHD). It may help people whose immune symptoms are hard to control, but it is carefully limited to certain medical situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent (or otherwise legally consent).
- You have an immune problem diagnosed by a clinician (including acute or chronic GVHD).
- Your doctor believes there is no other treatment available that can reduce your symptoms.
- You do not have an illness caused mainly by a genetic defect or an infection.
- You are not currently sick with an infection and you do not have a history of cancer.
- You are not pregnant, and your expected life expectancy is more than 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using a combination of two types of immune cells (MSCs and CAR-T cells) to calm the immune system and treat autoimmune diseases. It may help people whose autoimmune condition is not well controlled with current medications.
This trial tests a new stem cell therapy for people with moderate to severe COPD who have not improved with standard treatments. The goal is to see if the therapy is safe and can help improve lung function.
This Phase 1 study tests Wharton Jelly mesenchymal stromal cells (a type of donor immune-support cell therapy) to help prevent GVHD, a common complication after an allogeneic stem cell transplant. It may help reduce the risk of immune attack on your body while you receive a stem cell transplant for blood cancer or related disorders.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This Phase 2 study tests medicines that calm inflammation before the first stem cell transplant. It aims to make transplant safer and more effective for people with certain inherited immune regulation or inflammatory conditions.
Hear when a new Immune Related Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.